Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Equity Ratio (2021 - 2025)

Historic Equity Ratio for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to 0.75.

  • Kiniksa Pharmaceuticals International's Equity Ratio fell 449.63% to 0.75 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.75, marking a year-over-year decrease of 449.63%. This contributed to the annual value of 0.76 for FY2024, which is 942.45% down from last year.
  • Kiniksa Pharmaceuticals International's Equity Ratio amounted to 0.75 in Q3 2025, which was down 449.63% from 0.75 recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Equity Ratio registered a high of 0.88 during Q1 2023, and its lowest value of 0.72 during Q1 2022.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's median Equity Ratio value was 0.83 (recorded in 2024), while the average stood at 0.81.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Equity Ratio tumbled by 1726.32% in 2022 and then soared by 2237.77% in 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Equity Ratio (Quarter) stood at 0.79 in 2021, then rose by 8.43% to 0.86 in 2022, then dropped by 3.25% to 0.83 in 2023, then decreased by 9.42% to 0.76 in 2024, then decreased by 0.48% to 0.75 in 2025.
  • Its Equity Ratio was 0.75 in Q3 2025, compared to 0.75 in Q2 2025 and 0.76 in Q1 2025.